Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sucha Nand

Showing results (21-30 of 28) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 28 results.
Blood|April 6, 2018
Comparable outcomes of patients eligible vs ineligible for SWOG leukemia studiesAbby Statler, Megan Othus, Harry P Erba, et al.
Leukemia Research|January 29, 2016
Association between early promoter-specific DNA methylation changes and outcome in older acute myeloid leukemia patientsNicholas J Achille, Megan Othus, Kathleen Phelan, et al.
Leukemia & Lymphoma|May 21, 2020
Safety of gemtuzumab ozogamicin as monotherapy or combination therapy in an expanded-access protocol for patients with relapsed or refractory acute myeloid leukemiaEunice S Wang, Richard Aplenc, Deborah Chirnomas, et al.
Oncotarget|January 1, 2017
Sensitizing leukemia stem cells to NF-κB inhibitor treatment in vivo by inactivation of both TNF and IL-1 signalingJing Li, Andrew Volk, Jun Zhang, et al.
Blood|August 5, 2004
Overexpression of the NOTCH ligand JAG2 in malignant plasma cells from multiple myeloma patients and cell linesChristiane Houde, Yulin Li, Lynda Song, et al.
Cell Reports|March 25, 2015
FAK mediates a compensatory survival signal parallel to PI3K-AKT in PTEN-null T-ALL cellsDewen You, Junping Xin, Andrew Volk, et al.
The Journal of Experimental Medicine|May 21, 2014
Co-inhibition of NF-κB and JNK is synergistic in TNF-expressing human AMLAndrew Volk, Jing Li, Junping Xin, et al.
Cancer|February 11, 2004
A randomized controlled trial of darbepoetin alfa administered as a fixed or weight-based dose using a front-loading schedule in patients with anemia who have nonmyeloid malignanciesPaul J Hesketh, Francis Arena, Dhimant Patel, et al.
Pageof 3

Showing results (21-30 of 28) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 28 results.
Blood|April 6, 2018
Comparable outcomes of patients eligible vs ineligible for SWOG leukemia studiesAbby Statler, Megan Othus, Harry P Erba, et al.
Leukemia Research|January 29, 2016
Association between early promoter-specific DNA methylation changes and outcome in older acute myeloid leukemia patientsNicholas J Achille, Megan Othus, Kathleen Phelan, et al.
Leukemia & Lymphoma|May 21, 2020
Safety of gemtuzumab ozogamicin as monotherapy or combination therapy in an expanded-access protocol for patients with relapsed or refractory acute myeloid leukemiaEunice S Wang, Richard Aplenc, Deborah Chirnomas, et al.
Oncotarget|January 1, 2017
Sensitizing leukemia stem cells to NF-κB inhibitor treatment in vivo by inactivation of both TNF and IL-1 signalingJing Li, Andrew Volk, Jun Zhang, et al.
Blood|August 5, 2004
Overexpression of the NOTCH ligand JAG2 in malignant plasma cells from multiple myeloma patients and cell linesChristiane Houde, Yulin Li, Lynda Song, et al.
Cell Reports|March 25, 2015
FAK mediates a compensatory survival signal parallel to PI3K-AKT in PTEN-null T-ALL cellsDewen You, Junping Xin, Andrew Volk, et al.
The Journal of Experimental Medicine|May 21, 2014
Co-inhibition of NF-κB and JNK is synergistic in TNF-expressing human AMLAndrew Volk, Jing Li, Junping Xin, et al.
Cancer|February 11, 2004
A randomized controlled trial of darbepoetin alfa administered as a fixed or weight-based dose using a front-loading schedule in patients with anemia who have nonmyeloid malignanciesPaul J Hesketh, Francis Arena, Dhimant Patel, et al.
Pageof 3